Table 2 Clinical characteristics and chemistry results according to mean platelet volume

Age, yrs.

58.2 ± 10.3

55.7 ± 12.1

57.4 ± 9.2

0.566

Male, n (%)

33(89.2)

31(73.8)

27(81.8)

0.216

BMI, kg/m²

26.1 ± 3.5

25.9 ± 3.4

25.5 ± 2.6

0.758

LVEF, %

60.0(53.0, 65.0)

63.0(60.0, 65.0)

65.0(58.0, 68.0)

0.026

 Hypertension, n (%)

20(54.1)

20(47.6)

24(72.7)

0.083

 Diabetes, n (%)

14(37.8)

14(33.3)

7(21.2)

0.304

 Hyperlipidemia, n (%)

34(91.9)

38 (90.5)

29(87.9)

0.850

 Previous PCI, n (%)

15(40.5)

12(28.6)

10(30.3)

0.489

 Previous MI, n (%)

29(78.4)

28(66.7)

16(48.5)

0.031

 Previous stroke, n (%)

4(10.8)

4(9.5)

6(18.2)

0.494

 Statins, n (%)

37(100.0)

42(100.0)

33(100.0)

1.000

 ACEI, n (%)

17(45.9)

14(33.3)

9(27.3)

0.245

 ARB, n (%)

6(16.2)

3(7.1)

6(18.2)

0.313

 β-blocker, n (%)

36(97.3)

34(81.0)

28(84.8)

0.078

 Hemoglobin, g/L

140.0 ± 13.0

147.0 ± 13.2

148.8 ± 11.9

0.011

 LDL-C, mmol/L

2.4(1.7, 2.8)

2.2(1.6, 2.8)

2.0(1.7, 2.2)

0.457

 HsCRP, mg/L

3.1(1.2, 8.4)

1.8(0.9, 4.7)

1.5(0.5, 6.7)

0.232

 AST, U/L

25.0(20.5, 85.0)

25.5(20.8, 38.2)

21.0(16.5, 28.0)

0.010

 ALT, U/L

26.0(22.0, 42.5)

32.0(21.5, 52.0)

29.0(17.0, 40.0)

0.474

 Platelet, 10⁹ cells/L

257.3 ± 73.4

243.9 ± 63.2

201.4 ± 48.3

0.001

 Maximal LT changes in response to 5 μM ADP, %

17.0(12.4, 25.7)

20.6(12.1, 36.5)

32.0(16.4, 51.5)

0.006

 PRI, %

21(11.5, 28.0)

31.0(23.0, 66.5)

61.0(30.5, 79.0)

< 0.001

 Percentage of HPR-LTA, %

0(0)

6(14.3)

5(15.2)

0.049

 Percentage of HPR-VASP, %

4(10.8)

15(35.7)

20(60.6)

< 0.001

 Traditional therapy, n (%)

6(16.2)

18(42.9)

22(66.7)

< 0.001

 New therapy, n (%)

31(83.8)

24(57.1)

11(33.3)

< 0.001